Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 17 of 40 for:    atricure

FREEZE-AFIB Post-Market Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05089877
Recruitment Status : Not yet recruiting
First Posted : October 22, 2021
Last Update Posted : October 22, 2021
Sponsor:
Information provided by (Responsible Party):
AtriCure, Inc.

Brief Summary:

This study is proposed herein is to gather clinical data on the safety and performance of the CRYOF device.

Specifically, data from this study will be used for submission to regulatory authorities in Europe, China and other geographies as needed.


Condition or disease Intervention/treatment
Atrial Fibrillation Atrial Flutter Device: Surgical Ablation

Layout table for study information
Study Type : Observational
Estimated Enrollment : 150 participants
Observational Model: Case-Only
Time Perspective: Other
Official Title: Outcomes of Surgical AF Ablation Using cryoICE Cryoablation System
Estimated Study Start Date : November 1, 2021
Estimated Primary Completion Date : October 1, 2022
Estimated Study Completion Date : March 1, 2023

Resource links provided by the National Library of Medicine



Intervention Details:
  • Device: Surgical Ablation
    The AtriCure cryoICE® cryoFORMTM cryoablation probe is used in the cryosurgical treatment of cardiac arrhythmias by freezing target tissues, creating an inflammatory response (cryonecrosis) that blocks the electrical conduction pathway.


Primary Outcome Measures :
  1. Freedom from Death, Stroke (regardless of level of disability), myocardial infarction, and major bleeding events. [ Time Frame: 30 days post procedure ]
    Death, stroke (regardless of level of disability), myocardial infarction, and major bleeding events within 30-days of the index ablation procedure. Measured by number of patients with Treatment-Related Adverse Events.

  2. Freedom from any documented AF, AFL or AT lasting >30 seconds in the duration of the last follow-up visit off antiarrhythmic therapy (except of AADs at doses not exceeding those previously failed [ Time Frame: 12-24 months post procedure ]
    Freedom from any documented atrial fibrillation (AF), atrial flutter (AFL), or atrial tachycardia (AT) lasting >30 seconds in duration at the last follow-up visit off antiarrhythmic therapy (except of AADs at doses not exceeding those previously failed). Measured by 24-hour Holter Monitoring.


Secondary Outcome Measures :
  1. Freedom from any documented AF, AFL, or AT lasting >30 seconds at the last follow-up visit regardless of Class I or III AADs [ Time Frame: 12-24 months post procedure ]
    Freedom from any documented AF, AFL, or AT lasting >30 seconds at the last follow-up visit regardless of Class I or III AADs.

  2. Freedom from any documented AF, AFL, or AT lasting >30 seconds at the last follow-up visit in the absence of Class I or III AADs. [ Time Frame: 12-24 months post procedure ]
    Freedom from any documented AF, AFL, or AT lasting >30 seconds at the last follow-up visit in the absence of Class I or III AADs.

  3. Acute procedural success defined as documentation of sinus rhythm at the end of the procedure. [ Time Frame: At end of procedure ]
    Acute procedural success defined as documentation of sinus rhythm at the end of the procedure.


Other Outcome Measures:
  1. Freedom from pacemaker implant or overall device or Surgical Ablation procedures Related to Adverse Events [ Time Frame: 12-24 months post procedure ]
    Freedom from pacemaker implant or overall device or Surgical Ablation procedures Related to Adverse Events



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients who have undergone concomitant surgical AF ablation using the CRYOF device under investigation.
Criteria

Inclusion Criteria:

  1. Subject is greater than or equal to 18 years of age.
  2. Subject has documented history of atrial fibrillation.
  3. Subjects who received surgical ablation for their atrial fibrillation using CRYOF and on whom at least the following lesions were performed: Left and right pulmonary vein isolation, roof and floor lines, mitral annulus line and a connecting lesion from left atrial appendage to left pulmonary vein coronary sinus lesion and LAA exclusion , with a lesion duration of at least 2 minutes.
  4. Stable subject that underwent non-emergent cardiac surgical procedure(s) on cardiopulmonary bypass including open-heart surgery for one or more of the following: mitral valve repair or replacement, aortic valve repair or replacement, tricuspid valve repair or replacement, or coronary artery bypass procedures, or atrial septal defect (ASD) repair
  5. Left Ventricular Ejection Fraction ≥ 30% (determined by echocardiography or cardiac catheterization performed within 90 days of enrollment as documented in patient medical history).
  6. Subject is willing and able to provide written informed consent.
  7. Subject is willing and able to return for scheduled follow-up visits.

Exclusion Criteria:

  1. Stand-alone AF without indication(s) for concomitant CABG and/or valve surgery.
  2. Previous left sided ablation procedures procedure.
  3. Untreated atrial flutter and symptomatic ventricular arrythmia
  4. Known carotid artery stenosis greater than 80% prior to index ablation procedure.
  5. Prior history of ischemic stroke or hemorrhagic stroke
  6. History of MI with ST elevation within 6 weeks prior to the index ablation
  7. Documented AF duration of greater than 10 years.
  8. Large left atrial size i.e., LA diameter >7 cm prior to the index ablation procedure.
  9. Subjects with active systemic infection prior to index ablation procedure.
  10. Subjects who had documented severe peripheral arterial occlusive disease defined as claudication with minimal exertion prior to the ablation procedure.
  11. Subjects with history of renal failure requiring dialysis or hepatic failure prior to the ablation procedure.
  12. A known drug and/or alcohol addiction.
  13. Mental impairment or other conditions which may not allow the subject to understand the nature, significance, and scope of the study.
  14. Subjects who are pregnant
  15. Subjects who had preoperative need for mechanical circulatory support or intravenous inotropes.
  16. Subjects who are on anti-arrhythmic drug therapy for the treatment of another arrhythmia.
  17. Subjects in currently undergoing chemotherapy.
  18. Subjects on long term treatment with oral or injected steroids (not including intermittent use of inhaled steroids for respiratory diseases).
  19. Subjects who had known connective tissue disorders at the time of index ablation procedure
  20. Subjects who had known hypertrophic obstructive cardiomyopathy at the time of index ablation procedure
  21. Subjects with known cold agglutinin.
  22. Subjects who had or tested positive for COVID-19
  23. Subjects with bleeding disorders and/or inability to receive anticoagulation
  24. Subjects undergoing aortic dissection surgery as index procedure.
  25. Cardiac surgical re-intervention since the index cardiac surgery with concomitant AF ablation procedure

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05089877


Contacts
Layout table for location contacts
Contact: Erik J Fransen, MSc, PhD +31622707172 efransen@atricure.com
Contact: Nfii Ndikintum, PhD (513) 644-8192 NNdikintum@atricure.com

Sponsors and Collaborators
AtriCure, Inc.
Layout table for additonal information
Responsible Party: AtriCure, Inc.
ClinicalTrials.gov Identifier: NCT05089877    
Other Study ID Numbers: CP-2021-02
First Posted: October 22, 2021    Key Record Dates
Last Update Posted: October 22, 2021
Last Verified: August 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by AtriCure, Inc.:
Surgical ablation
Cryo probe
Additional relevant MeSH terms:
Layout table for MeSH terms
Atrial Fibrillation
Atrial Flutter
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes